Aldeyra Therapeutics, Inc. (FRA:137)
3.525
-0.055 (-1.54%)
At close: Jan 9, 2026
Aldeyra Therapeutics Employees
Aldeyra Therapeutics had 9 employees as of December 31, 2024. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
€4,601,772
Market Cap
212.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -1 | -10.00% |
| Dec 31, 2023 | 10 | -5 | -33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | 11 | -9 | -45.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 317,562 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,995 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Aldeyra Therapeutics News
- 12 days ago - Aldeyra Therapeutics: Reproxalap's March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
- 26 days ago - Aldeyra Therapeutics Inc Regulatory Update Conference Call Transcript - GuruFocus
- 26 days ago - Aldeyra Therapeutics, Inc. (ALDX) Discusses PDUFA Target Action Date Extension for Reproxalap in Dry Eye Disease Transcript - Seeking Alpha
- 26 days ago - Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxalap - GuruFocus
- 26 days ago - Aldeyra drops as FDA delays review of marketing application for lead drug - Seeking Alpha
- 26 days ago - FDA Extends Review Timeline For Aldeyra's Reproxalap NDA In Dry Eye Disease - Nasdaq
- 26 days ago - Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA - GuruFocus
- 27 days ago - Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease - Business Wire